Sector
PharmaceuticalsOpen
₹1,284Prev. Close
₹1,254.5Turnover(Lac.)
₹4,470.78Day's High
₹1,505.4Day's Low
₹1,26852 Week's High
₹3,37952 Week's Low
₹1,242.95Book Value
₹393.7Face Value
₹10Mkt Cap (₹ Cr.)
1,266.63P/E
35.99EPS
34.84Divi. Yield
0.48Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 8.51 | 8.51 | 8.51 | 8.51 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 304.21 | 283.88 | 259.93 | 229.07 |
Net Worth | 312.72 | 292.39 | 268.44 | 237.58 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 219.35 | 208.47 | 169.42 | 134.78 |
yoy growth (%) | 5.21 | 23.04 | 25.7 | 9.32 |
Raw materials | -61.7 | -53.39 | -22.74 | -23.31 |
As % of sales | 28.12 | 25.61 | 13.42 | 17.29 |
Employee costs | -39.11 | -33.45 | -37.15 | -22.28 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 53.25 | 60.06 | 41.22 | 43.7 |
Depreciation | -9.5 | -9.63 | -9.38 | -5.45 |
Tax paid | -13.73 | -14.88 | -10 | -13.14 |
Working capital | 22.11 | 12.78 | 30.69 | 13.13 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 5.21 | 23.04 | 25.7 | 9.32 |
Op profit growth | -15.86 | 36.55 | 6.29 | 20.73 |
EBIT growth | -12.94 | 38.35 | 0.52 | 26.8 |
Net profit growth | -0.96 | 27.79 | 2.17 | 22.52 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 304.55 | 266.09 | 235.01 | 214.33 | 183.27 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 304.55 | 266.09 | 235.01 | 214.33 | 183.27 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 15.25 | 19.56 | 14.16 | 4.68 | 6.37 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,698.35 | 132.17 | 4,16,392.59 | 1,181.05 | 0.78 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,549.7 | 73.93 | 1,53,257.67 | 594 | 0.52 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,444.25 | 25.02 | 1,16,434.16 | 1,438.15 | 0.9 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,183.9 | 60.01 | 1,09,468.65 | 485 | 0.87 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,458.1 | 51.7 | 99,973.97 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
Bhupendra V Gandhi
Non Executive Director
Sanjiv D Gandhi
Alternate Director
Nina Gandhi
Independent Director
Sandhya Patel
Independent Director
Ashok Bhadakal
Independent Director
Ameet Desai
Managing Director & CEO
Rajiv D Gandhi
Non Executive Director
Ravin Gandhi
Executive Director
PRIYA RAJIV GANDHI
Independent Director
Anil Jain
Independent Director
Jatin Yagneshbhai Trivedi
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Hester Biosciences Ltd
Summary
Hester Biosciences Limited is one of the leading and pioneering animal healthcare companies in India. The Company was incorporated in April, 1987 and is principally engaged in manufacturing of Poultry vaccines and Large Animal Vaccines and trading of Poultry and Large animal and Petcare health products having its manufacturing set up at Meda Adraj Village, Mehsana District, Gujarat. The Company engages in two business verticals, namely Poultry Healthcare and Animal Healthcare. It has built a presence in several regions of Africa and in numerous nations, including Vietnam, Indonesia, Nepal, and Bangladesh. The products and services offered include over 51 vaccines and 70+ health products. In addition, it offers a vast selection of pharmaceuticals, feed supplements, and disinfectants for poultry and large animals.The Company markets and distributes veterinary and pharmaceutical products like animal health products, poultry vaccines, poultry diagnostic, laboratory kits and reagents. It markets the veterinary products of many international companies including Ghen Corporation, Japan; Maine Biological Laboratories, US; Idexx Corporation, US; International Diagnostic Systems Corporation, US; Biogal Galed Laboratories, Israel; and Kemin Europa, Belgium.The companys own production of veterinary vaccines (in Vials) is expected to commence soon. HPL has technical collaborations with Maine Biological Laboratories and Ghen Corporation.During 1996-97, company successfully implemented vete
Read More
The Hester Biosciences Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1488.95 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Hester Biosciences Ltd is ₹1266.63 Cr. as of 01 Apr ‘25
The PE and PB ratios of Hester Biosciences Ltd is 35.99 and 3.28 as of 01 Apr ‘25
The 52-week high/low is the highest and lowest price at which a Hester Biosciences Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Hester Biosciences Ltd is ₹1242.95 and ₹3379 as of 01 Apr ‘25
Hester Biosciences Ltd's CAGR for 5 Years at 5.92%, 3 Years at -20.69%, 1 Year at -10.04%, 6 Month at -48.97%, 3 Month at -47.71% and 1 Month at -16.22%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.